Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y.--(BUSINESS WIRE)--March 22, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Swiss health authority, Swissmedic, has approved Tarceva™ (erlotinib) for the...
PRNewswire DEERFIELD, Ill. Fujisawa Healthcare, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the use of micafungin sodium, the antifungal product for...
PRNewswire DEERFIELD, Ill. and BASEL, Switzerland Fujisawa Healthcare, Inc. and Roche Pharmaceuticals today announced a partnership for the U.S. co-promotion of MYCAMINE™ (micafungin sodium)...
Read more about Fujisawa Healthcare, Inc. and Roche Announce Co-promotion of MYCAMINE™
First Astellas Product Launched in the United States PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. announced today the launch and availability of their newest systemic anti-fungal agent...
Read more about Anti-Fungal Agent MYCAMINE™ Available to Physicians
Tarceva is the Only Epidermal Growth Factor Receptor (EGFR) Therapy to Show an Improvement in Survival in Pancreatic Cancer HOLLYWOOD, Fla.--(BUSINESS WIRE)--Jan. 27, 2005--OSI Pharmaceuticals,...
Follow U.S. news
